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hospital characteristics, patterns of medication used, and
outcome measures. Multivariate analyses such as general
linear model (GLM) and logistic regression were per-
formed. RESULTS: Logistic regression results show that
hospital size (p < 0.0001), hospital type (p < 0.0472), type
of procedure (p < 0.0001), and hospitals having a care-
plan for surgical site infection (p < 0.0032) were signiﬁ-
cantly associated with the probability for patients to get
the recommended prophylaxis. Based on the results from
GLM regression analysis, older age is signiﬁcantly asso-
ciated with longer LOS (p < 0.0001) for all procedures.
Scheduled operations (p < 0.0001) and receiving the rec-
ommended prophylaxis (p < 0.0214) were signiﬁcantly
related to a decrease in LOS. Also, a signiﬁcant effect on
LOS was observed, depending what kind of surgical pro-
cedure patients underwent and what hospital they were
admitted. CONCLUSIONS: Compliance with practice
guidelines may reduce LOS, which suggests improved
patient outcomes and decreased health care costs.
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OBJECTIVE: A cost-beneﬁt analysis was conducted to
compare the costs associated with operating a poison
center to the beneﬁts derived from center availability.
METHODS: Costs were measured as the direct cost of
operating the center, including personnel, reference
sources for clinical information, equipment, and admin-
istrative overhead expenses. Beneﬁts were measured as
the opportunity cost of alternative treatment strategies
had a poison center not been available to callers. Data
were collected through a concurrent telephone survey of
poison center callers at the time of the initial poison expo-
sure call. Callers were asked a series of three questions
regarding actions they would have taken if the poison
center were not available. Follow-up calls were used to
assess actions callers actually took after calling the center.
Inputs and beneﬁts were valued using average local prices
for medical services from a state paid claims database. A
decision analysis model was constructed to calculate the
expected cost of poison treatments under two scenarios
(poison center available or not). Model probabilities were
derived from the percentage of callers indicating that they
would pursue a particular course of action. RESULTS: A
total of 1695 poison exposure cases were included in the
analysis. The average cost per poison exposure associated
with not having a poison center available was $62.40.
This ﬁgure represents the beneﬁt of having a poison
center. The average cost of managing a poison call was
$8.52, yielding a beneﬁt per call ratio of $7.32. This ratio
reﬂects the amount of additional health care expenditures
avoided per dollar expended in a poison center consulta-
tion. A sensitivity analysis was conducted to assess the
impact of changes in emergency service use on the model.
CONCLUSION: Based on our analysis, the immediate
information and treatment advice available through a
state-run poison center has as a positive societal value.
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OBJECTIVES: The focus of present health political dis-
cussion in Germany is concentrated on ﬁnancing as an
instrument to meet the future needs of German popula-
tion. Government wants to cut back beneﬁts by offering
alternative funding mechanism, which is tax ﬁnancing
and additional patient payments. The recent and signiﬁ-
cant changes to Health care funding in Germany is
reviewed. METHODS: A literature review was conducted
to analyze a number of strengths to the ﬁnancing and
funding arrangements in the German Health care system.
The potential advantages for priorities, efﬁciency, and
equity from this structure of ﬁnancing are considered. The
results will be compared to the design of the currently
started plans for a further Health care reform in Germany
with focus on ﬁnancing. RESULTS: The current most
important scheme of social health insurance (SHI) ﬁnance
intended to mobilize resources for health care, to insure
against risk, and to provide stable ﬁnance seems for the
government not to be any longer the funding mechanism
that helps to control costs and to secure access to broad
priority services. Government intends to use ﬁnance
mechanism to shift low priority services into SHI and put
high priority services into ﬁnance mechanism of user
charges. The level of priority services is—so far—not a
result of discussions in the community. Financial fairness
is best served by the cornerstone of more progressive 
prepayments as it is the case for SHI premiums instead 
of patient payments. Co-payments have the effect of
rationing use health care services but does not effect in
rationalizing its demand by insured. CONCLUSIONS:
Currently risks are distributed according to ability to pay
rather than to risk of disease. Financing fairness is best
served by the cornerstone of progressive prepayments 
as it is the case for SHI premiums instead of patient 
payments.
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OBJECTIVE: Although tube feeding is commonly used in
hospitals in the UK, clinician interviews showed that no
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systematic nutritional screening was undertaken on
admission. This study demonstrates which patients
receive enteral tube feeding and estimates the hospital
burden of such patients. METHODS: The CHKS hospi-
tal dataset contains aggregated, anonymised information
on diagnosis, hospital experience, and patient demo-
graphics for over 80 million episodes in the UK, repre-
senting 55% of hospital admissions. It was used to
identify patients who received enteral nutrition (using
OPCS-4 codes) and compared their hospital stays with a
control group who had the same primary diagnoses but
were not tube fed. Both groups were analysed for comor-
bidities, procedures, and length of stay (LOS). RESULTS:
We identiﬁed 14,328 patients who were tube fed in
2001/2002 out of 947,897 patients who were hospi-
talised for various diseases/conditions: dysphagia, cancer;
stroke; neurological, respiratory and GI disorders, cystic
ﬁbrosis, feeding difﬁculties/anorexia, renal disease, and
others. Tube fed patients had 28,768 separate episodes
compared to 2,502,937 episodes for patients having the
same disease/condition who did not receive any tube
feeds. Overall, tube fed patients had one additional pro-
cedure, i.e. the tube feeding procedure, during their 
hospital stay compared to controls (average of 2.3 
procedures across disease groups for tube fed patients).
Daily tube feeding costs vary between £10.20 and
£13.18. This represents only 2.8–3.6% of the daily inpa-
tient cost of, for example, £359 in a surgical ward. CON-
CLUSIONS: Over 26,000 patients who are tube fed 
are admitted yearly in England. However the number of
patients receiving tube feeding is very restricted, even
though the cost is a small fraction of hospital costs. Does
every patient who could beneﬁt from tube feeding receive
it? If not, should tube feeding remain severely restricted
when it is known that its use could improve patients’
recovery?
HEALTH CARE POLICY—New Health Technology
Studies
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OBJECTIVE: The Centers for Medicare and Medicaid
Services (CMS) computes payment for high cost new tech-
nology drugs and biologicals in the hospital outpatient
prospective payment system (OPPS) under two methods.
This study examines the results of CMS computations
over the initial thirty months of the hospital outpatient
prospective payment system. METHODS: Phase I: CMS
methods used ﬁrst for payment of high cost new tech-
nology drugs and biologicals eligible for initial pass-
through payment status and second for subsequent
expired pass-through payment status were identiﬁed.
Underlying assumptions were examined and formal
methodology evaluations were collected. Phase II: A
thirty-month time line was constructed. The assumptions
utilized for CMS changes in payment status at month one,
month nineteen and month twenty-eight were examined
and analyzed. Analyses employing descriptive statistics
identiﬁed components of payment assumptions and vari-
ations between the assumptions utilized at each of the
three time line milestones. Findings were compared to a
sample of actual CMS payments received by hospitals.
RESULTS: A database of methodology explanations,
visuals, and evaluations was created. An evolutionary
time line of CMS methodologies and underlying assump-
tions was created. Study analyses revealed a statistically
signiﬁcant differential between aggregated mean payment
amounts for the same high cost new technology drugs and
biologicals at the ﬁrst and the third milestones of the time
line. Over one-half of the affected drugs and biologicals
sustained payment rate reductions exceeding forty
percent. CONCLUSIONS: CMS payment methods and
underlying assumptions for expired pass-through drugs
and biologicals is ﬂawed. In addition, the basic hospital
drug acquisition cost assumptions made by CMS are not
consistent with actual hospital data. These ﬁndings will
be of use to economists, cost accountants, and policy
makers interested in arriving at equitable payments for
high cost new technology drugs that are essential to
modern health care in U.S. hospitals.
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OBJECTIVES: This outlines the lessons learned by the
author who is Director of one of the six units in the 
UK that undertake independent academic evaluations of
Technology Assessment Reviews for NICE. The author
provides an insiders’ view of the major issues that arise
in managing the evaluation process. METHODS: The
Liverpool TAR group assists NICE to provide guidance
on appropriate treatment for speciﬁc conditions in spe-
ciﬁc sub-groups of patients. The aim is to standardise clin-
ical practice around the most clinically and cost-effective
interventions. The aim is to spread cost-effective new
treatments more quickly across the health service to
promote successful innovation on the part of the phar-
maceutical industry. The importance of this UK initiative
goes beyond its national borders as other governments 
are guided by NICE judgements in their reimbursement
decisions and many are developing similar systems of
appraisal. RESULTS: The paper analyses the impact of
the 6-stage structure of NICE evaluation and assesses
how generalisable the process may be to other countries.
Issues underlying the targeting of NICE appraisals will
also be examined together with the challenges presented
